Mavacamten is a breakthrough therapy option for hypertrophic cardiomyopathy, a condition where the heart muscle becomes thick and stiff, making it harder for the heart to pump blood effectively. Mavacamten works by targeting the underlying cause of the disease, reducing the excessive contraction of heart muscle cells. This results in improved heart function and symptoms such as shortness of breath and fatigue. Mavacamten is a promising new option for patients with hypertrophic cardiomyopathy, providing hope for improved quality of life and long-term outcomes. Here Prof. Barlis introduces this therapy and provides some important updates on this condition and medication.
22 авг 2024
